Literature DB >> 425995

The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers.

R E Sampliner, F A Hamilton, O A Iseri, E Tabor, J Boitnott.   

Abstract

Two hundred four volunteer blood donors with hepatitis B surface antigen found in their blood were followed for 3 to 44 months. The annual clearance rate of this antigen was 1.7%. Liver enzyme levels (aminotransferase) were elevated in 45 (22.1%) on at least one occasion, in 26 (12.7%) for one month or more, and in 13 for more than six months. Liver biopsies were performed on 17 chronic carriers with normal enzymes and nonspecific histologic abnormalities were found in 14 and mild diffuse hepatitis in three. Seventeen carriers with abnormal enzymes were biopsied, and specimens revealed chronic active hepatitis (CAH) in seven, including two with bridging necrosis and three with cirrhosis. CAH was found in 7 of 26 (26.9%) carriers with abnormal liver enzymes persisting for at least one month and 4 of 13 (30.8%) with abnormal liver enzymes for more than six months.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 425995     DOI: 10.1097/00000441-197901000-00002

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  21 in total

Review 1.  Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies.

Authors:  Ralph Carmel; Mona Sarrai
Journal:  Curr Hematol Rep       Date:  2006-03

2.  Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses.

Authors:  Kali Zhou; Caitlin Contag; Evans Whitaker; Norah Terrault
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-01-22

Review 3.  Natural history of the HBsAg carrier.

Authors:  M G Anderson; I M Murray-Lyon
Journal:  Gut       Date:  1985-08       Impact factor: 23.059

4.  Spontaneous hepatitis B surface antigen clearance in a long-term follow-up study of patients with chronic type B hepatitis. Lack of correlation with hepatitis C and D virus superinfection.

Authors:  L C Da Silva; C L Madruga; F J Carrilho; J R Pinho; A Saéz-Alquezar; C Santos; L Bassit; C Barreto; L E Fonseca; V A Alves; R Leitão; R Vianna; R A Cardoso; A V França; L C Gayotto
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

Review 5.  Interferon in the management of chronic hepatitis B.

Authors:  R P Perrillo
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

Review 6.  Hepatitis B virus infection. Current concepts of chronicity and immunity.

Authors:  G N Vyas; H E Blum
Journal:  West J Med       Date:  1984-05

Review 7.  Hepatitis B in pregnancy.

Authors:  J A Arevalo
Journal:  West J Med       Date:  1989-06

8.  Economic benefits of hepatitis B vaccination at sexually transmitted disease clinics in the U.S.

Authors:  M'Kiaira K Miriti; Kaafee Billah; Cindy Weinbaum; Julie Subiadur; Richard Zimmerman; Paula Murray; Robert Gunn; Joanna Buffington
Journal:  Public Health Rep       Date:  2008 Jul-Aug       Impact factor: 2.792

9.  HBsAg seroclearance in Chinese patients receiving lamivudine therapy for chronic hepatitis B virus infection.

Authors:  Man-Fung Yuen; Danny Ka-Ho Wong; He-Jun Yuan; Siu-Man Sum; Ching-Lung Lai
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

10.  Ethnic differences in incidence of hepatitis B surface antigen seroclearance in a real-life multicenter clinical cohort of 4737 patients with chronic hepatitis B infection.

Authors:  L H Nguyen; J Hoang; N H Nguyen; V D Vu; C Wang; H N Trinh; J Li; J Q Zhang; M H Nguyen
Journal:  Aliment Pharmacol Ther       Date:  2016-07-01       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.